semaglutide vs tirzepatide doses Evaluating Dose Titration in and for Weight Loss: A Retrospective Academic Call Center Study How Many Units Is 2.5

Weeks 1 through 4: Reduce to 12.5 mg weekly

In comparative studies, complete suppression of -arrestin recruitment produced slower internalization, reduced downregulation, and longer-lasting cAMP signaling than semaglutide [52], indicating that semaglutide retains functionally meaningful arrestin engagement, even if not at the highest level among GLP-1R agonists

Short non-diabetic data support remaining at 2.5 mg when weight and insulin-resistance markers are already moving and tolerability favors a hold. The label still positions 2.5 mg as the starter before 5 mg, so it is a defensible low-dose floor for selected users rather than a replacement for the 5 mg obesity-trial floor

Are breastfeeding or planning to breastfeed

Ziltivekimab Ziltivekimab, an anti-inflammatory fully human monoclonal antibody to interleukin (IL)-6, is being studied in ZEUS, a phase 3 CV outcomes trial

Warnings and Precautions 5.1 Risk of Thyroid C-Cell Tumors In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)]